Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down After Analyst Downgrade

Mineralys Therapeutics, Inc. (NASDAQ:MLYS)’s share price gapped down before the market opened on Thursday after The Goldman Sachs Group lowered their price target on the stock from $28.00 to $24.00. The stock had previously closed at $10.63, but opened at $10.15. The Goldman Sachs Group currently has a buy rating on the stock. Mineralys Therapeutics shares last traded at $10.28, with a volume of 14,179 shares.

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Thursday.

Insider Buying and Selling

In related news, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $97,888.70. Following the completion of the transaction, the chief financial officer now owns 226,097 shares of the company’s stock, valued at approximately $2,057,482.70. This trade represents a 4.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jon Congleton sold 18,333 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $9.06, for a total transaction of $166,096.98. Following the sale, the chief executive officer now directly owns 877,608 shares in the company, valued at $7,951,128.48. This trade represents a 2.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 33.24% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MLYS. JPMorgan Chase & Co. boosted its holdings in shares of Mineralys Therapeutics by 2,251.5% in the 4th quarter. JPMorgan Chase & Co. now owns 503,590 shares of the company’s stock valued at $6,199,000 after buying an additional 482,174 shares during the last quarter. Jennison Associates LLC raised its position in Mineralys Therapeutics by 55.4% during the fourth quarter. Jennison Associates LLC now owns 1,082,006 shares of the company’s stock worth $13,319,000 after acquiring an additional 385,726 shares in the last quarter. Candriam S.C.A. acquired a new stake in Mineralys Therapeutics in the fourth quarter valued at $3,758,000. Franklin Resources Inc. grew its position in shares of Mineralys Therapeutics by 17.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,745,513 shares of the company’s stock valued at $21,138,000 after acquiring an additional 262,922 shares during the period. Finally, Caligan Partners LP increased its stake in shares of Mineralys Therapeutics by 31.6% during the 3rd quarter. Caligan Partners LP now owns 981,155 shares of the company’s stock worth $11,882,000 after purchasing an additional 235,397 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors.

Mineralys Therapeutics Stock Performance

The company has a market capitalization of $509.64 million, a P/E ratio of -3.13 and a beta of 1.44. The stock’s fifty day moving average price is $11.17 and its 200-day moving average price is $12.01.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.02. On average, research analysts predict that Mineralys Therapeutics, Inc. will post -3.63 EPS for the current fiscal year.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.